https://nova.newcastle.edu.au/vital/access/ /manager/Index en-au 5 Patients' and clinicians' preferences for adjuvant chemotherapy in endometrial cancer: an ANZGOG substudy of the PORTEC-3 intergroup randomised trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:26036 Wed 11 Apr 2018 10:39:36 AEST ]]> Developing clinical indicators for oncology: the inaugural cancer care indicator set for the Australian Council on Healthcare Standards https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48764 Wed 05 Apr 2023 13:48:31 AEST ]]> Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: the PARAGON trial – ANZGOG 0903 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45582 p = 0.002), cognitive functioning (45 vs 19%: p = 0.021), fatigue (47 vs 19%: p = 0.015) and global health status (42 vs 9%: p = 0.003). Conclusion: Although the objective response rate to anastrozole was relatively low, clinical benefit was observed in 44% of patients with ER/PR positive metastatic endometrial cancer and associated with an improvement in QOL.]]> Wed 02 Nov 2022 10:37:04 AEDT ]]> PARAGON: a phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45708 Fri 04 Nov 2022 10:18:27 AEDT ]]>